Ptc Therapeutics, Inc., was incorporated as a Delaware corporation on March 31, 1998. PTC Therapeutics, LLC is a biopharmaceutical company focused on the discovery and development of proprietary small molecule drugs for oral use in the post-transcriptional control process. At the same time, the company's research and development plans are aimed at multiple therapeutic areas, and the company is particularly focused on the development and commercialization of treatments for orphan and ultra-orphan disorder diseases. The company's leading product candidate is ataluren, which is used in the treatment of an inherited disease called nonsense mutation gene mutation that occurs during the treatment process.